Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)-The MAM Study

Vaccine

Volumn 33, Issue 42, 2015, Pages 5640-5646

  Giuliano, Anna R ^a   Isaacs Soriano, Kimberly ^a   Torres, B Nelson ^a   Abrahamsen, Martha ^a   Ingles, Donna J ^a   Sirak, Bradley A ^a   Quiterio, Manuel ^b   Lazcano Ponce, Eduardo ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

HPV; Human papillomavirus; Mid adult men; Vaccine

Indexed keywords

WART VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANXIETY DISORDER; ARTICLE; COUGHING; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EPIPHORA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NOSE OBSTRUCTION; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEROCONVERSION; SORE THROAT; THORAX PAIN; VACCINATION; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; FLORIDA; MEXICO; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FLORIDA; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNOGLOBULIN G; MALE; MEXICO; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS;

EID: 84943449279     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.072     Document Type: Article

References (22)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans 2007, 90:1-636. World Health Organization, International Agency for Research on Cancer.
2. Giuliano A. International HPV incidence among men ages 18-70 years. International papillomavirus congress and clinical workshop 2009.
3. Giuliano A.R., Lu B., Nielson C.M., Flores R., Papenfuss M.R., Lee J.H., et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008, 198:827-835.
4. Partridge J.M., Hughes J.P., Feng Q., Winer R.L., Weaver B.A., Xi L.F., et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007, 196:1128-1136.
5. Giuliano A.R., Nyitray A.G., Kreimer A.R., Pierce Campbell C.M., Goodman M.T., Sudenga S.L., et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer 2015, 136(12):2752-2760.
6. Dunne E.F., Nielson C.M., Stone K.M., Markowitz L.E., Giuliano A.R. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006, 194:1044-1057.
7. Stone K.M., Karem K.L., Sternberg M.R., McQuillan G.M., Poon A.D., Unger E.R., et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002, 186:1396-1402.
8. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. New Eng J Med 2011, 364:401-411.
9. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin Diagn Lab Immunol 2003, 10:108-115.
10. Hillman R.J., Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Vardas E., et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 2012, 19:261-267.
11. Brown B., Blas M., Cabral A., Carcamo C., Gravitt P., Halsey N. Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers. Vaccine 2012, 30:2309-2314.
12. Skinner S.R., Szarewski A., Romanowski B., Garland S.M., Lazcano-Ponce E., Salmeron J., et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014, 384:2213-2227.
13. Giuliano A.R., Lee J.H., Fulp W., Villa L.L., Lazcano E., Papenfuss M.R., et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011, 377:932-940.
14. Kreimer A.R., Pierce Campbell C.M., Lin H.Y., Fulp W., Papenfuss M.R., Abrahamsen M., et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013, 382:877-887.
15. Nyitray A.G., Carvalho da Silva R.J., Baggio M.L., Lu B., Smith D., Abrahamsen M., et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis 2011, 203:49-57.
16. Giuliano A.R., Viscidi R.P., Lu B., Torres B.N., Lin H.Y., Fulp W., et al. HPV seroconversion differs significantly by HPV type and anatomic site of infection among men: results from the HPV Infection in Men (HM) Study. 29th international papillomavirus conference and clinical workshop 2014.
17. Lu B., Viscidi R.P., Wu Y., Lee J.H., Nyitray A.G., Villa L.L., et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 2012, 72:676-685.
18. Sudenga S.L., Pierce Campbell C.M., Lin H.Y., Fulp W., Messina J.L., Stoler M.H., et al. Genital HPV infection and progression to external genital lesions: the HIM Study. Eur Urol 2015, Epub 2015 Jun 4; PMID: 26051441.
19. Pierce Campbell C.M., Kreimer A., Viscidi R., Lin H.Y., Fulp W., Abrahamsen M., et al. Serum antibodies and risk of subsequent oral HPV infection in men: the HIM Study. 29th international papillomavirus conference and clinical workshop 2014.
20. Chaturvedi A.K., Anderson W.F., Lortet-Tieulent J., Curado M.P., Ferlay J., Franceschi S., et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013, 31:4550-4559.
21. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis 2007, 26:201-209.
22. Palefsky J.M., Giuliano A.R., Goldstone S., Moreira E.D., Aranda C., Jessen H., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New Eng J Med 2011, 365:1576-1585.